Validation of a 2-Gene Blood Test for Kawasaki Disease in Febrile Children - Report - MDSpire

Validation of a 2-Gene Blood Test for Kawasaki Disease in Febrile Children

  • By

  • Ho-Chang Kuo

  • Xing Xue

  • Fang Liu

  • Richard D. Mortensen

  • C. James Chou

  • Bo Jin

  • Juan Wei

  • Qiong Luo

  • Ken-Pen Weng

  • Mindy Ming-Huey Guo

  • Kuender D. Yang

  • Kuo-Jung Su

  • Shih-Ting Kang

  • Sun Kim

  • Weiwei Li

  • James Schilling

  • Zhi Han

  • Naoto Ozawa

  • Takumi Ichikawa

  • Henry Chubb

  • Scott R. Ceresnak

  • Gary L. Darmstadt

  • Doff McElhinney

  • Harvey J. Cohen

  • Xuefeng B. Ling

  • May 28, 2026

  • 0 min

Share

Clinical Report: Assessment of a Two-Gene Blood Test for Diagnosing Kawasaki Disease

Overview

This study evaluates a two-gene blood test for Kawasaki disease (KD) diagnosis, demonstrating its potential to improve diagnostic accuracy. The test, based on IFI27 and MCEMP1 gene expression, was assessed in a cohort of 541 children, showing promising results in distinguishing KD from other febrile illnesses.

Background

Kawasaki disease is a significant cause of acquired heart disease in children, with timely diagnosis and treatment being crucial to prevent complications. Traditional diagnostic methods are often subjective and can lead to delays, particularly in cases with incomplete clinical features. The development of molecular biomarkers, such as the two-gene signature evaluated in this study, could enhance diagnostic precision and facilitate earlier intervention.

Data Highlights

Specify the total number of febrile controls and clarify 'indeterminate results'.

Key Findings

  • The two-gene signature (IFI27 and MCEMP1) was tested in a cohort of 541 children with fever.
  • Out of 445 determinate classifications, 209 KD cases were correctly identified.
  • The assay demonstrated a misclassification of 8 KD cases and 42 febrile controls.
  • 96 participants fell into the indeterminate range, indicating biological overlap.
  • The study adhered to the STARD reporting guidelines, ensuring robust methodological standards.

Clinical Implications

The two-gene blood test could serve as a valuable tool for clinicians in diagnosing Kawasaki disease, particularly in cases with incomplete clinical features. Early and accurate diagnosis may lead to timely treatment, potentially reducing the risk of coronary complications in affected children.

Conclusion

The evaluation of the two-gene blood test highlights its potential to enhance the diagnostic process for Kawasaki disease, warranting further validation in clinical practice. This advancement may significantly impact the management of febrile children presenting with symptoms suggestive of KD.

Related Resources & Content

  1. JAMA Network Open, 2023 -- A Step Forward Toward Improved Kawasaki Disease Diagnosis
  2. Pediatric Cardiology, 2007 -- Genetic Variations in Human Leukocyte Antigen Genes Among Korean Pediatric Patients with Kawasaki Disease
  3. Pediatric Cardiology, 2024 -- Evaluation of Risk Assessment Models for Predicting Coronary Artery Dilation in Kawasaki Disease within a North American Population
  4. Update on Diagnosis and Management of Kawasaki Disease: A Scientific Statement From the American Heart Association
  5. New England Journal of Medicine, 2026 -- Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease
  6. Pediatric Cardiology — Distinguishing Kawasaki Disease from Multisystem Inflammatory Syndrome in Pediatric Patients Through Blood Composite Scores: Implications for Clinical Outcomes and Predictive Measures
  7. American Heart Association's Updated Scientific Statement
  8. CDC Overview on Kawasaki Disease
  9. Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease | New England Journal of Medicine
  10. Diagnosis of Bacterial Infection Using a 2-Transcript Host RNA Signature in Febrile Infants 60 Days or Younger | Infectious Diseases | JAMA | JAMA Network

Original Source(s)

Related Content